Oslo - Delayed Quote NOK

Photocure ASA (PHO.OL)

56.50

+2.30

+(4.24%)

At close: April 25 at 4:25:12 PM GMT+2

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.

PR Newswire last month

PHCUF
Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in Madrid, Spain, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on recurrence risk and ability to help urologists make the best bladder cancer management choices for their patients.

PR Newswire last month

PHCUF
New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective was to assess if blue light cystoscopy (BLC®) aided TURBT has an impact on the clinical outcomes of patients with NMIBC*. Results of the real-world evidence study show that BLC was associated with a statistically significant 38% reduction in risk of recurr

PR Newswire last month

PHCUF
Photocure ASA: Results for the fourth quarter of 2024

Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA of NOK 8.5 million (NOK 29.9 million). Photocure expects product revenue growth in the range of 7% to 11% and year-over-year EBITDA improvement in 2025. While the company is not providing a specific EBITDA guidance range, Photocure expects continued operating leverage flow-through in its core commercial business and significant growth in mile

PR Newswire 2 months ago

PHCUF
News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces an update regarding its ongoing collaboration with Richard Wolf to develop a high-definition flexible blue light cystoscope for global commercialization. The development process for an optimized solution is progressing on plan, with an interim solution now available to centers in all countries where System blue and other components are cleared.

PR Newswire 2 months ago

PHCUF
Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), in San Francisco. The abstract discusses the role of Blue Light Cystoscopy in identifying tumors undetected by WLC leading to necessary upstaging of patient pathology. Consequently, when using Blue Light Cystoscopy with Cysview,

PR Newswire 2 months ago

PHCUF
Photocure ASA: Results for the third quarter of 2024

Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBITDA of NOK 5.0 million (NOK 3.3 million) for the Company. Photocure reiterates its 2024 financial guidance and continues to expect consolidated product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses.

PR Newswire 5 months ago

PHCUF
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira® (APL-1702) for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) has been published by the 27th Chinese Society of Clinical Oncology (CSCO) Annual Meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month patho

PR Newswire 6 months ago

PHCUF
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to initiate a Named Patient Program (NPP) enabling bladder cancer patients in South Africa to receive blue light cystoscopy (BLC®) with Hexvix®.

PR Newswire 6 months ago

PHCUF
Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that international multicenter Phase III clinical trial data for its non-surgical treatment for cervical HSIL (High-Grade Squamous Intraepithelial Lesion) product candidate Cevira® (APL-1702) have been accepted for oral presentation by the International Photodynamic Therapy & Photodiagnosis Update Conference in Germany on September 17, 2024, focusing on th

PR Newswire 7 months ago

PHCUF
Photocure ASA: Results for the second quarter of 2024

Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.4 million in the second quarter of 2024 (Q2 2023: NOK 115.9 million) and EBITDA of NOK 27.8 million (NOK 23.4 million). Photocure reiterates its 2024 financial guidance of product revenue growth of 6% to 9% in constant currency and positive EBITDA excluding business development expenses. Photocure now expects new and upgraded Saphira™ installations in the U.S. in the range of 55 to 70 towers

PR Newswire 8 months ago

PHCUF
Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. The partnership between Photocure and Richard Wolf is focused on developing technologically advanced flexible blue light cystoscopy (BLC®) equipment for the global market so that physicians who tre

PR Newswire 9 months ago

PHCUF
Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC®) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S. leveraging ForTec's utilization-driven mobile equipment business model.

PR Newswire 10 months ago

PHCUF
Photocure ASA - Annual general meeting held

Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).

PR Newswire 10 months ago

PHCUF
Photocure ASA: Results for the first quarter of 2024

Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 116.8 million in the first quarter of 2024 (Q1 2023: NOK 105.9 million), and EBITDA of NOK 7.9 million (NOK -1.2 million) following positive operational developments and cost control. The Company reiterates its business and financial guidance for 2024 with 40 to 70 new and upgraded Saphira™ blue light tower installations during the year, product revenue growth of 6% to 9% in constant currency, and positive EBITDA excluding b

PR Newswire 11 months ago

PHCUF
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for the regulatory review of Cevira® (APL-1702, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) for potential marketing authorization in China. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non

PR Newswire 11 months ago

PHCUF
Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX, USA. The results of the BRAVO study performed within the VA healthcare system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a blue light cystoscop

PR Newswire 11 months ago

PHCUF
Photocure ASA - Notice of the Annual General Meeting 23 May 2024

Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal").

PR Newswire 11 months ago

PHCUF
Photocure ASA: Annual Report 2023

Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.

PR Newswire 11 months ago

PHCUF

Performance Overview

Return	PHO.OL	OBX Total Return Index (OBX.OL)
YTD	-8.87%	+4.10%
1-Year	+3.86%	+8.57%
3-Year	-49.82%	+25.01%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Photocure ASA (PHO.OL)

Photocure appoints Jane Healy as Vice President and General Manager EMEA

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence

Photocure ASA: Results for the fourth quarter of 2024

News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared

Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025

Photocure ASA: Results for the third quarter of 2024

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Photocure ASA: Results for the second quarter of 2024

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure ASA - Annual general meeting held

Photocure ASA: Results for the first quarter of 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure ASA - Notice of the Annual General Meeting 23 May 2024

Photocure ASA: Annual Report 2023

Performance Overview